ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Psychiatric Disorders Often Overlooked By Oncologists

September 28, 2007

In Brief: NCAB Dec. Meeting Includes Biologics Symposium; Epidemiology Center Grant Program Disapproved

November 29, 1985

Study: End-of-Life Chemotherapy Leads to More Deaths in Hospital

March 28, 2014

May issue of Business & Regulatory Report, 8 additional pages, included.

May 28, 2004

Early-Stage HER2+ Breast Cancer Patients Are At Significant Risk Of Recurrence

December 26, 2008

DeVita Frustrated By Gap Between Bypass, “Real” Budgets, Seeks Better System To Develop Priorites

April 24, 1981